Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma

Tomoyuki Satake; Taro Shibuki; Kazuo Watanabe; Mitsuhito Sasaki; Hiroshi Imaoka; Shuichi Mitsunaga; Motohiro Kojima; Masafumi Ikeda

doi:10.3389/fonc.2023.1234113

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma

Front Oncol. 2023 Jul 21:13:1234113. doi: 10.3389/fonc.2023.1234113. eCollection 2023.

Authors

Tomoyuki Satake¹, Taro Shibuki¹, Kazuo Watanabe¹, Mitsuhito Sasaki¹, Hiroshi Imaoka¹, Shuichi Mitsunaga¹, Motohiro Kojima², Masafumi Ikeda¹

Affiliations

¹ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
² Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan.

Abstract

Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver cancers. Therapeutic strategies for patients with cHCC-CCA are limited, and no standard systemic treatment has been established for unresectable cHCC-CCA. Here, we present six cases of cHCC-CCA treated with atezolizumab plus bevacizumab. We observed three partial responses and one stable disease as the best responses; two of these patients were still being treated with atezolizumab plus bevacizumab at the time of reporting (at least five months of treatment), whereas the remaining two patients were unable to continue treatment owing to adverse events. Atezolizumab plus bevacizumab may be an effective treatment for unresectable cHCC-CCA.

Keywords: atezolizumab; bevacizumab; case series; combined hepatocellular-cholangiocarcinoma; immunotherapy.

Publication types

Case Reports